Exendin-4 was ultimately synthesized to Exenatide, a GLP-1RA with a half-life sufficient to permit clinical use in treating type 2 diabetes, the first in a new generation of drugs that followed
Its no wonder research shows that those with high levels of vitamin D or its receptors are more likely to be naturally resistant to HIV-1 infection
Hiensch, demonstrates that supervised, structured, and Trastuzumab Deruxtecan Shows Promise in Treating HER2-Positive Biliary Tract Cancer Aug 6, 2024 Trastuzumab Deruxtecan Shows Promise in Treating HER2-Positive Biliary Tract Cancer A recent phase II clinical trial conducted across five institutions in Japan has investigated the efficacy of Aspirin reduces the risk of colorectal cancer in individuals with unhealthy lifestyle Aug 2, 2024 Aspirin reduces the risk of colorectal cancer in individuals with unhealthy lifestyle A study published in JAMA Oncology investigated the association between aspirin use and colorectal cancer (CRC) Combining PSMA-PET and PROMISE accurately stratifies high-risk and low-risk groups for overall survival in early and late stages of prostate cancer Jul 31, 2024 Combining PSMA-PET and PROMISE accurately stratifies high-risk and low-risk groups for overall survival in early and late stages of prostate cancer A recent multicentre retrospective study aimed to evaluate the effectiveness of PSMA-PET imaging and the PROMISE Explore content categories
As it stands right now, there is no conclusive evidence regarding the number of ESIs that can be performed in a year or a lifetime
Superficial confirmed BCC can be treated with imiquimod (subsidised under Special Authority criteria) when standard treatment options, including surgical excision, are contraindicated or inappropriate (Table 2)
